Shareholder letter...
Shareholder letter...
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma Reports Second Quarter 2023 Financial Results
Aug 7, 2023 • 9:00 EDT | Read More
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
Aug 3, 2023 • 1:25 EDT | Read More